Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (October 2006)
25 slides from Bayer's technical presentation, Oct 31, 2006
Slide 1: New Tools for the Lifescience Industry – From Systems Biology to Microtechnology
New Tools for the Lifescience Industry – From Systems Biology to Microtechnology Innovations-Perspektive 2006 Leverkusen, October 31, 2006 Dr. Helmut Mothes, SVP Process Technology Dr. Klaus Sommer, SVP Business Management
Slide 2: Topics
Topics ¾ Overview on Bayer Technology Services ¾ Technology Strategy and Platforms ¾ New Tools for Active Substances Development → Assay Technology → Systems Biology → Microtechnology ¾ Outlook
Slide 3: Bayer: Science for a Better Life
Bayer: Science for a Better Life Health Care Crop Material Science Science „Bayer‘s Products and Services are Designed to Benefit People and Improve their Quality of Life.“
Slide 4: BTS's Alignment
BTS´s Alignment Customer Support along the entire Process Life Cycle Product & Process Innovation Engineering Procurement Construction Process Optimization Troubleshooting
Slide 5: BTS Product Families
BTS Product Families Product & Process Engineering & Consulting & Plant Optimization Innovation Construction Services Consulting && Consulting Services Services BTS develops new processes and products BTS carries out global investment projects BTS optimizes production plants and products BTS offers
Slide 6: BTS International Presence
BTS International Presence Employees (10.2006) 2.170 Sales (2005) 358 Mio. Euro Belgium 80 Employees USA China 220 Employees 370 Employees (+ 200 Contractors) (+ 150 Contractors) Germany 1,200 Employees Mexico 280 Employees Switzerland Zeptosens AG 20 Employees
Slide 7: Strategy – Technology Roadmap
Strategy – Technology Roadmap Smart Operations Smartly Engineered Processes Cost Leadership / Commodities (e.g. Process Intensification/Integration) Materials with Functionality World Scale (e.g. Carbon Nanotubes enhanced Polymer) Supply Chain Optimized Integrated Products Operations Specialties, (e
Slide 8: Strategy – Technology Platforms
Strategy – Technology Platforms Catalysis Synthesis Processing Biotechnology Product Design Technology Nanotechnology Temperature [°C ] 500 400 Source 300 Sink D31-Gen. Platforms D31 200 Hot Utility D3 D6 D6-Gen. 100 Cold Utility D3-Gen. 0 Cooling water/Air R(-20) Enthalpy -100 Materials „DPP-Tool“
Slide 9: Systems Biology and Microtechnology – Technologies for better Efficiencies
Systems Biology and Microtechnology – Technologies for better Efficiencies From Target ... ... to Approval Assessment, Containment and Shift of Risk Reduced Risk into early Phases Faster Time to Market Optimal Exploitation of Market Potential Lower Capital Investment with modular, intensified, flexi
Slide 10: Biomarker – Response Prediction for Cancer Therapies
Biomarker – Response Prediction for Cancer Therapies Prediction of tumor response on cancer therapies based on gene expression rates. 0.2 0.15 0.1 0.05 0 Selection of predictive markers -0.05 -0.1 -0.15 -0.2 out of more than 20000 genes -0.25 -0.3 0.2 0.1 0 -0.1 -0.2 0 0.2 0.4 0.6 requires sophistic
Slide 11: Planar Waveguide – A new Assay Technology
Planar Waveguide – A new Assay Technology BTS blood sample fragmentation, labeling planar waveguide amplification, labeling, clean up current biochip Planar Waveguide Technology represents a promising Assay Technology for Biomarker and Drug Development
Slide 12: Systems Biology of Thrombosis and Hemostasis
Systems Biology of Thrombosis and Hemostasis Inhibition (e.g. CardioAspirin or Rivaroxaban) and facilitation (Kogenate) of coagulation plays an important role in Bayer‘s portfolio Processes underlying blood clotting can be modeled very effectively While cancer is an established application of System
Slide 13: ZeptoMARK CeLyA: From Cells to Protein Profiles
ZeptoMARK® CeLyA: From Cells to Protein Profiles BTS Rapid, sensitive and robust Profiling generates the necessary Input for Model Validation and Biomarkers Identification
Slide 14: Pharmaco-Kinetic Simulation
Pharmaco-Kinetic Simulation Simulation enables Prediction of Drug Performance for Children prior to Clinical Tests
Slide 15: The Integrated Systems Biology Approach
The Integrated Systems Biology Approach Treatment 6 4 2 Effect Effect 0 CT T CT T CT CT CT CT CT CT CT B D r ) 87 ) (E ) 82 2A ng MG bl ffe FR 1R From Cell Signaling Technology PD 1 FR - IT 3 r-a T8 Bu 1 2 1 2 EN KB F- G G - T3 bc IS (IG M FL U G 3 In-Silico Technology Assay Technology (PWG) Systems
Slide 16: Challenges for Active Compound Synthesis and Manufacturing
Challenges for Active Compound Synthesis and Manufacturing From Lab ... ... to Manufacturing ¾ Time to Market is decisive for active compound development ¾ Selected synthesis pathways and early product specification define options for clinical development or field trials and future manufacturing ¾ P
Slide 17: Microtechnology – A New Approach for Rapid Development
Microtechnology – A New Approach for Rapid Development Charts Cryostatic Process T4 T5 Hydrocyclone Photoreactor Temperature reactor Control T1 T3 T6 Pressure Precipitation Mixer Sensor Hardware reactor Microtechnology will accelerate Process Development requiring a Paradigm Change in Laboratories
Slide 18: Microtechnology – Scale-up with Speed & Efficiency
Microtechnology – Scale-up with Speed & Efficiency Laboratory Scale-up Production 20 → 1000 l/h 20 → 250 l/h Precipitation Modular design accelerates Process Development, avoids Scale-up Issues, improves Flexibility and reduces Investment
Slide 19: Microtechnology – A Concept for better Processes
Microtechnology – A Concept for better Processes Scale-up: 100x Oxidation Oxidation 10000 80 A B C 70 space-time-yield [kg/m3*s] 1000 60 Temperature [°C] 50 100 40 30 ¾ Conventional batch process 10 20 → costly safety measures → 50°C, > 1h 10 ¾ Microtechnology based process 1 Lab Scale Lab Scale Lab
Slide 20: Microtechnology – A Solution for special Polymer Production
Microtechnology – A Solution for special Polymer Production Challenge: ¾ Microtechnology-based Processes for low-volume, high-value polymers for → medical applications → tailor-made materials → nanocomposites Results: ¾ Reliable process performance superior to conventional process ¾ New concepts fea
Slide 21: Smart Factory: Fast - Efficient - Modular - Flexible
Smart Factory : Fast - Efficient - Modular - Flexible A Vision for Active Ingredient Development and Production for Pharmaceuticals and Agrochemicals?
Slide 22: Systems Biology and Microtechnology – From Drugs to Personalized Medicine
Systems Biology and Microtechnology – From Drugs to Personalized Medicine Drug Manufacturing Diagnostic Systems Array-, Biochip-, Biomarker Technologies Systems Biology Understanding Biological Systems (Omics-technologies, data mining and mechanistic modeling) Drug Delivery Systems Triggered and/or
Slide 23: Systems Biology and Microtechnology – From Biofuels to Biomaterials
Systems Biology and Microtechnology – From Biofuels to Biomaterials Substrate 2 Substrate 1 Product + By - products + X X X s Cell mas Systems Biology and Microtechnology could support Industrial Biotechnology leading to better Processes and Plants
Slide 24: Systems Biology and Microtechnology – From Crop Protection to Smart Breeding
Systems Biology and Microtechnology – From Crop Protection to Smart Breeding Active Ingredient Production Ingredient Manufacturing with Microtechnology Mycotoxin / GMO-Detection with Planar Wave Guide Assay Technology Metabolic Treatment Pathway Engineering Computational Biomarkers Biology Effect Fr
Slide 25: Forward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial